Browse Articles

A recent study published in theJournal of Clinical Oncologyhas indicated that married cancer patients fare better than singletons.

Powers and colleagues characterize tumour-promoting fibroblast–basal breast cancer cell crosstalk.

Mutations in the metabolic gene isocitrate dehydrogenase 2 (IDH2) drive the development of leukaemia and sarcoma in vivo.

There is an emerging association between the microbiota and carcinogenesis. How might the microbiota modulate tumorigenesis, and what do we need to understand to more firmly conclude that the microbiome causes cancer?

In this Review, the authors examine the aetiological, pathogenic and clinical features that are associated with cancers harbouring oncogenic fusion kinases, the clinical outcomes with targeted therapies, and strategies to discover additional kinases that are activated by chromosomal rearrangements in solid tumours.

The influence of the microenvironment on tumour progression is becoming clearer. This Review addresses the role of transforming growth factor-β in the regulation of components of the tumour microenvironment.

Inhibition of macrophage colony-stimulating factor 1 receptor (CSF1R) can block glioblastoma growth by changing the phenotype of tumour-associated macrophages from pro-tumorigenic to antitumorigenic.

Two papers published inCancer Discoveryunveil the molecular mechanisms that underpin the improved response of patients with high-risk prostate cancer to ionizing radiation in the presence of androgen deprivation therapy.

This Opinion article outlines the roles of vesicle trafficking pathways in various phenotypes shown by cancer cells, especially loss of polarity and invasion, and argues that although these proteins are not drivers of transformation, they are integral to maintaining neoplastic phenotypes.

Two new studies have highlighted the lack of understanding many women have about their own breast cancer risk and treatment.

Simon Boulton and colleagues have found that the 3′–5′ superfamily 2 helicase HELQ is important to prevent germ cell attrition and tumour development in mice.

Three papers assess the mutational landscapes of human tumours, and all three find evidence for a role of APOBECs.

Myeloid-derived suppressor cells (MDSCs) remain steeped in mystery and controversy — how do we identify them? How are they recruited to the tumour microenvironment? How do they suppress antitumour immunity? This Timeline article discusses the discovery of MDSCs and what we know now — and need to know in the future — about the role of MDSCs in cancer biology.

What can we learn about cancer stem cells and tumour tissue hierarchy from what we know about stem cells? Read this Opinion article to find out how our knowledge of normal stem cells applies to cancer stem cells in solid tumours.

This Review discusses mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and molecularly targeted therapies, which share many features. It is hoped that an improved understanding of the molecular basis of resistance will lead to rational drug combinations and predictive biomarkers.

Anaplastic lymphoma kinase (ALK) is commonly altered — through mutation, overexpression or translocation — in many types of cancer, but the role of ALK signalling in mammalian cells and tumours remains enigmatic. What can we learn from model systems? And what progress has been made in targeting this receptor tyrosine kinase?

Krüppel-like factor (KLF) transcriptional regulators have diverse functions in many cancer-relevant processes. This Review discusses the context-dependent roles for KLFs in different cancers and identifies key questions for the field.